CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS
Open Access
- 8 July 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (15)
Abstract
Idiopathic pulmonary fibrosis (IPF) is a severe, diffuse, progressive, and fibrosing interstitial disease leading to respiratory failure and death in the absence of organ transplantation. Substantial evidence has confirmed the pivotal role of fibroblasts in the progression of IPF, yet effective therapeutic options are scarce. Single-cell transcriptomics profiling revealed that among the diverse fibroblast subsets, FAP1 + alveolar fibroblasts (AFs) were pivotal for the progression of IPF. On the basis of these findings, we developed FAP1-targeting chimeric antigen receptor cytotoxic effector regulatory T cells (CAR-cTregs), which leveraged the targeted killing advantage of the currently trending CAR-based immunotherapy for tumors and incorporated the immunosuppressive functions of Tregs to mitigate the inflammation caused by both the disease itself and CAR-T cell infusion. Accordingly, CAR-cTregs were constructed to effectively eliminate FAP1 + fibroblasts in vitro. This cytotoxic effect could be abrogated by inhibitors of the granzyme B/perforin pathway. In the bleomycin-induced PF model, CAR-cTregs were found to reverse fibrosis characterized by diminished recruitment of fibrocytes and improved remodeling of epithelial cells. Together, our results demonstrate that CAR-cTregs can serve as a promising therapeutic option for IPF and provide an alternative strategy for treating multiple chronic inflammatory diseases by inducing both cytotoxicity and immunosuppression.Keywords
Funding Information
- National Natural Science Foundation of China (82100354,81970345,82470284)
- Support Plan of Science and Technology Department of Sichuan Province, China (2023NSFSC0002,2023NSFSC1637,2023NSFSC2569)
- “Qimingxing” Research Fund for Young Talents (HXQMX0024)
- West China Hospital Postdoctoral Science Foundation (2020HXBH107)
This publication has 57 references indexed in Scilit:
- T regulatory cells and attenuated bleomycin-induced fibrosis in lungs of CCR7-/- miceFibrogenesis & Tissue Repair, 2010
- Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoNature Immunology, 2009
- Redirection of Regulatory T Cells With Predetermined Specificity for the Treatment of Experimental Colitis in MiceGastroenterology, 2008
- Generation of Potent and Stable Human CD4+ T Regulatory Cells by Activation-independent Expression of FOXP3Molecular Therapy, 2008
- Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytesExperimental Hematology, 2006
- Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorderRespiratory Research, 2001
- Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound SitesThe Journal of Immunology, 2001
- Regulated Production of Type I Collagen and Inflammatory Cytokines by Peripheral Blood FibrocytesThe Journal of Immunology, 1998
- A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.Proceedings of the National Academy of Sciences, 1996
- The T-body approach: potential for cancer immunotherapySpringer Seminars in Immunopathology, 1996